Comparing SG&A Expenses: Bausch Health Companies Inc. vs Protagonist Therapeutics, Inc. Trends and Insights

SG&A Expenses: Bausch Health vs Protagonist Therapeutics

__timestampBausch Health Companies Inc.Protagonist Therapeutics, Inc.
Wednesday, January 1, 201420263000001860000
Thursday, January 1, 201526827000002963000
Friday, January 1, 201628100000006961000
Sunday, January 1, 2017258200000011779000
Monday, January 1, 2018247300000013697000
Tuesday, January 1, 2019255400000015749000
Wednesday, January 1, 2020236700000018638000
Friday, January 1, 2021262400000027196000
Saturday, January 1, 2022262500000031739000
Sunday, January 1, 2023291700000033491000
Loading chart...

Unlocking the unknown

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Bausch Health Companies Inc. and Protagonist Therapeutics, Inc. from 2014 to 2023.

Bausch Health Companies Inc.

Bausch Health, a major player, consistently reported high SG&A expenses, peaking at approximately $2.9 billion in 2023. This represents a 44% increase from 2014, reflecting strategic investments in marketing and administration.

Protagonist Therapeutics, Inc.

In contrast, Protagonist Therapeutics, a smaller biotech firm, saw its SG&A expenses grow from $1.9 million in 2014 to $33.5 million in 2023, a staggering 1,700% increase. This growth underscores its aggressive expansion and development strategies.

This comparison highlights the diverse financial strategies within the pharmaceutical sector, offering insights into how companies allocate resources to drive growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025